Heron Therapeutics, Inc. Share Price & Technical Analysis
HRTX · $0.86 (-1.15%)
Healthcare / Biotechnology
$0.86
-1.15%
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It o…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-25% return in May, -6% avg return in past 3 year May month.
-16% return in 2026, 29% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 0% | -8% | -33% | 50% | -25% | – | – | – | – | – | – | – | -16% |
| 25 | 6% | 47% | -8% | 9% | -24% | 11% | -15% | -18% | -7% | -8% | 0% | 18% | 11% |
| 24 | 41% | 13% | 4% | -18% | 61% | -5% | -14% | -37% | 5% | -15% | -33% | 25% | 26% |
| 23 | 4% | -11% | -37% | 50% | -54% | 0% | 42% | -6% | -37% | -40% | 100% | 42% | 51% |
| 22 | -5% | -18% | 4% | -21% | -27% | -15% | 0% | 46% | 2% | -10% | -31% | -11% | -85% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$178.40M
P/E ratio
—
52W high
$2.30
52W low
$0.74
Volume
10,49,775
Beta
1.71
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Heron Therapeutics, Inc. share price today?
- Heron Therapeutics, Inc. (HRTX) last traded around $0.86 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does HRTX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for HRTX. Download the app for real-time alerts.
- How can I analyze Heron Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.